^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Ewing Sarcoma |
| Drug: | seclidemstat (SP2577) (LSD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Salarius Pharmaceuticals Receives FDA Fast Track Designation for Lead Drug Candidate, Seclidemstat, in Relapsed or Refractory Ewing Sarcoma
Published date:
12/16/2019
Excerpt:
...Salarius Pharmaceuticals, Inc...announced today that its lead investigational drug candidate, Seclidemstat, has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with Ewing sarcoma who have relapsed or are refractory to standard-of-care therapy.
